Article · 7 Oct 2025
Research articlePublished 15 Jan 2018
ROLE OF ORAL MIFEPRISTONE AS A CERVICAL PRIMING AGENT FOR INDUCTION OF LABOUR
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
BACKGROUND Mifepristone is a 19 nor-Steroid with a greater affinity for the progesterone receptor and thus blocks the action of progesterone at a cellular level. As a fall in the level of progesterone considered one of the important events in the onset of spontaneous labour, it therefore seems likely that this drug may be useful on induction. Aim- To study the effectiveness and safety of Mifepristone as a cervical priming agent for induction of labour to determine the Maternal and foetal outcome. MATERIALS AND METHODS This prospective clinical trial was carried out in the Department of Obstetrics and Gynaecology, K.A.P.V Medical College & Mahatma Gandhi Memorial Hospital, Trichy during the period of January 2016 to December 2016 in 100 patients divided into study and control group equally. RESULTS In this study, study population comprised of 100 patients with equal no of patients in the study and control group. 66 (66%) patients were primi gravida, 24 (24%) were multigravida, with no significant difference across the groups. The mean Bishop score at inclusion was 1.48 in the study group and 1.12 in the control group with no significant differences between the groups. The mean treatment to induction to active stage interval was 24.08 hours in the Mifepristone treated group when compared to 30.25 hours in the Prostaglandin treated group. Subjects in the Mifepristone group progressed about 6 hours (mean difference) earlier than subjects in placebo group to active stage of labour and this difference was statistically significant. Mean induction to delivery interval was 28.60 in Mifepristone group when compared to 35.44 in placebo group. The rate of normal and assisted vaginal deliveries was 96% in the mifepristone treated group when compared to 72% in the placebo treated group with a significant P value The rate of caesarean deliveries (28.3%) was comparably less in the mifepristone treated group than the Prostaglandin treated group (46.6%). CONCLUSION In our study we found that Mifepristone as a pre-induction cervical ripening agent had better proven efficacy especially in primi gravida women as similarly proved by various other earlier standard trials. The need for reinduction/augmentation with other cerviprime agents/oxytocics were also reduced in the Mifepristone treated groups. The results are encouraging with no significant adverse effects on mother and fetus.
Subjects
Nursing & HealthcareAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Evidence-Based Medicine and Healthcare.
Article · 28 Jul 2025
Association between Admission Blood Pressure, Stroke Severity and Early Outcome in Thrombolysed Ischemic Stroke Patients: A Single Centre Experience from Northeast India
Article · 28 Mar 2025
Isolated Paralysis of Extensor Indicis and EDC Tendon of Index Finger Following Thompsonandrsquo;s Approach to Proximal Radius-Case Report
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Evidence-Based Medicine and Healthcare
- SubjectNursing & Healthcare
- BylineArticles whose byline prints “Bama Ramesh”
- BylineArticles whose byline prints “Vidyaravi”
- BylineArticles whose byline prints “Mareeswari”